The Food and Drug Administration on Tuesday authorized Mountain View’s 23andMe to sell a test for a breast cancer genetic mutation directly to consumers — the first time the agency has allowed the sale of a genetic test for cancer risk without a doctor’s prescription.The test analyzes a saliva sample to determine whether a woman has an increased risk for developing breast cancer by detecting genetic variants found on the BRCA1 and BRCA2 genes.